Model-Based Analysis of IGF-I Response, Dosing, and Monitoring for Once-Weekly Somapacitan in Children With GH Deficiency

Rasmus J. Kildemoes, Philippe F. Backeljauw, Michael Højby, Joanne C. Blair, Bradley S. Miller, Jun Mori, Yassine K. Lyauk

Research output: Contribution to journalArticlepeer-review

1 Scopus citations

Abstract

Context: Growth hormone (GH) replacement therapy improves longitudinal growth and adult height in children with GH deficiency (GHD). GH stimulates insulin-like growth factor (IGF)-I release, the biomarker used for monitoring GH activity during treatment. Objective: This study aims to provide model-based insights into the dose-IGF-I responses of once-weekly somapacitan, a novel long-acting GH, compared with daily GH in children with GHD. Methods: Analyses included dosing information and 1473 pharmacokinetic samples from 210 somapacitan-treated pediatric patients with GHD across 3 trials, including phase 1 (NCT01973244), phase 2 (NCT02616562; REAL 3), and phase 3 (NCT03811535; REAL 4), as well as 1381 IGF-I samples from 186 patients with GHD treated with somapacitan in REAL 3 and REAL 4. Pharmacokinetic/pharmacodynamic modeling to characterize somapacitan dose-IGF-I response and predict the response to dosing day changes. Results: Relationships were established between somapacitan dose, exposure, change from baseline IGF-I SD score (SDS), and height velocity (HV). A linear model permitted the development of a tool to calculate estimated average weekly IGF-I exposure from a single IGF-I sample obtained at any time within the somapacitan dosing interval at steady state. In practice, the use of this tool requires knowledge of somapacitan injection timing relative to IGF-I sample collection timing. IGF-I SDS simulations support flexible dosing day changes while maintaining at least 4 days between doses. Conclusion: We characterized the dose-IGF-I response of somapacitan in children with GHD. To support physicians in IGF-I monitoring, we present a practical guide about expected weekly average IGF-I concentrations in these patients and provide insights on dosing day flexibility.

Original languageEnglish (US)
Article numberbvad115
JournalJournal of the Endocrine Society
Volume7
Issue number11
DOIs
StatePublished - Nov 1 2023

Bibliographical note

Publisher Copyright:
© The Author(s) 2023.

Keywords

  • IGF-I
  • dosing
  • growth hormone deficiency
  • monitoring
  • pharmacodynamics
  • pharmacokinetics
  • somapacitan

PubMed: MeSH publication types

  • Journal Article

Fingerprint

Dive into the research topics of 'Model-Based Analysis of IGF-I Response, Dosing, and Monitoring for Once-Weekly Somapacitan in Children With GH Deficiency'. Together they form a unique fingerprint.

Cite this